Genetic modification of whole tumor cells opens up new perspectives in the field of cancer immunotherapy and vaccine design. Based on a newly developed platform, scientists at Creative Biolabs provide services to engineer colorectal cancer cell LOVO with a synthetic gene circuit, enabling the production of immunomodulators to trigger an antitumor T cell response.

Introduction of LOVO Cell Line

The LOVO cell line is an immortal human carcinoembryonic antigen-producing colon carcinoma cell line. This cell line was isolated from the left supraclavicular metastatic site of a 56-year-old male with colorectal adenocarcinoma, Dukes' type C. The gene mutations of the LOVO cell line include APC, KRAS, BRAF, etc. The cells are negative for expression of CSAp (CSAp-) and colon antigen 3. It represents an in vitro model for human colon carcinoma. It presents most of the properties of intestinal cells, including the formation of acinar structures, microvilli, a glycocalyx, desmosomes, adherens, and tight junctions. LoVo cell line shows high metastatic potential.

Creative Biolabs has established a platform to turn cancer cells against themselves. Based on this platform, we can engineer LOVO line via several strategies (such as cytokine modification) for self-destruction.

Engineering LOVO Cell Service

Creative Biolabs provides a synthetic gene circuits platform that enables the tumor-specific expression of immunostimulators. The outputs of gene circuits included a cytokine, a synthetic immunomodulatory, target-specific aptamer, etc. The circuits can trigger selective T cell-mediated killing of cancer cells, but not of normal cells. The synthetic gene circuit platform can be easily tailored to target many different cancers.

• Engineering LOVO Cells with Cytokines Overexpression

Engineering patients' cancer cells or cancer cells is a promising method for cancer immunotherapy and vaccine research. Tumor cells genetically modified with cytokine genes as tumor vaccines comprise the greatest proportion of gene therapy approaches to cancer. We have developed engineered LOVO cells overexpressing cytokine for stronger T-cell activation. Engineered tumor cells with cytokine overexpression can enhance antitumor immunity since

• ✔ The whole tumor cell provides a polyvalent source of tumor-associated antigens;
• ✔ The secretion of cytokine by the modified tumor cells can greatly enhance the immune response.

The following are different cytokines you can choose to engineer.

• Other Strategies for Engineering LOVO Cells

In addition, we also have other off-the-shelf solutions that will quickly establish and advance your projects. These strategies to engineer LOVO cells include:

We offer turn-key or a la carte services customized to our client's needs. Our custom solutions team has extensive experience and expertise in engineering cancer cells. Contact us to develop a solution and timeline for your project.

References

1. Nissim, L.; et al. Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell. 2017, 171(5): 1138-1150. e15.
2. Nagai, E.; et al. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunology, Immunotherapy. 1998, 47(2): 72-80.

For Research Use Only | Not For Clinical Use